Business · Markets · 1 day ago
Aardvark investors face October 13 deadline to seek lead plaintiff role
A class action lawsuit has been filed against Aardvark Therapeutics, a company whose shares trade on the Nasdaq.
It covers certain investors who bought shares linked to the company’s February 2025 initial public offering or securities from February 13, 2025, through May 14, 2026.
The lawsuit alleges that Aardvark and other defendants misled investors about the safety of ARD-101 and its clinical, regulatory and commercial prospects.
These are allegations, and no class has been certified.
Investors who want to serve as lead plaintiff must ask the court by October 13, 2026.
The lead plaintiff would represent other class members in directing the case.
Investors can also remain absent class members for now, and their ability to share in a possible recovery does not depend on becoming lead plaintiff.
Aardvark Therapeutics investors have until October 13, 2026, to ask a court to appoint them lead plaintiff in a class action.
The lawsuit concerns securities tied to the company’s February 13, 2025 initial public offering and securities purchased through May 14, 2026.
The suit alleges that Aardvark and other defendants misrepresented the safety and prospects of the drug candidate ARD-101.
Rosen Law Firm says a class action lawsuit has already been filed.
The firm says investors may also remain absent class members without seeking the lead plaintiff role.
- Who
- Investors who purchased Aardvark Therapeutics securities covered by the lawsuit.
- What
- The October 13, 2026 deadline to move for appointment as lead plaintiff in a class action.
- When
- The deadline is October 13, 2026.
- Where
- The case is before a court; the article does not identify which court.
- Why
- The lawsuit alleges that defendants misrepresented ARD-101’s safety and its clinical, regulatory and commercial prospects.
This story does not have two clearly opposing sides.
No direct quotes in the coverage so far.
Aardvark Therapeutics held its initial public offering.
The lawsuit defines this period as the class period for covered securities purchases.
Investors seeking lead plaintiff status must move the court by this deadline.
- Company
- Aardvark Therapeutics, Inc.
- Ticker
- NASDAQ: AARD
- IPO date
- February 13, 2025
- Class period end
- May 14, 2026
- Lead plaintiff deadline
- October 13, 2026
Sources
Related news
Amazon in talks to buy AI startup Decart for about $7 billion
Apple reportedly cuts iPhone 18 Pro component orders by up to 20%
SpaceX spectrum deal deepens Starlink’s push into U.S. mobile service
Starbucks has explored a possible takeover of Chipotle
Netflix reportedly plans to cut 5% of its workforce
Meta bans ByteDance ads across its platforms in seven countries
Los Angeles Fine-Dining Restaurants Expand Non-Alcoholic Pairings
Isaias Shuts In More Than Two-Thirds of Gulf Oil Production
Bond Traders Look to Inflation Data and Fed Chair for Rate Signals
Apple reportedly cuts iPhone 18 Pro component orders by up to 20%
Nvidia in talks over investment in or acquisition of Reflection AI
